Opportunity Information: Apply for RFA DA 16 012
Apply for RFA DA 16 012
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279,.
- This funding opportunity was created on Dec 14, 2015 and posted on Dec 14, 2015.
- Applicants must submit their applications by Mar 02, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This grant opportunity, titled "Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01)" (Funding Opportunity Number RFA-DA-16-012), is a National Institutes of Health (NIH) discretionary research grant that aims to push forward hypothesis-driven studies at the intersection of HIV biology, gene regulation, and substance use or abuse. The central purpose is to encourage innovative research that explains how epigenomic mechanisms (such as chromatin organization, DNA methylation, and histone modifications) and non-coding RNA pathways (including regulatory RNAs that do not code for proteins) shape HIV infection and disease course when substance use is also part of the clinical picture. In other words, the FOA is looking for mechanistic work that connects molecular regulation in host cells to real outcomes in HIV persistence or progression, specifically under the modifying effects of drugs of abuse.
A major emphasis of the announcement is understanding how regulatory processes in the host genome influence where HIV integrates and how those integrated viral genomes are controlled afterward. Because HIV integration is not random and the local chromatin environment can strongly affect whether the virus is transcriptionally active or silent, the FOA highlights the need to uncover the epigenomic and non-coding RNA factors that guide both the selection of integration sites and the subsequent regulation of viral expression. This focus matters because integration site choice and epigenetic context are closely tied to whether HIV becomes part of a long-lived latent reservoir, which is a key barrier to curing infection.
Another priority is the application of this knowledge to the practical challenge of detecting and tracking latent HIV, particularly in cellular reservoirs that are difficult to study and treat, with special attention to the central nervous system (CNS). The opportunity points to the CNS as an important reservoir because latency and persistence in brain-associated cells can contribute to long-term complications and may be less responsive to standard treatment strategies. By clarifying how epigenomic states and non-coding RNAs maintain latency or permit intermittent reactivation, funded projects could lay groundwork for better biomarkers or monitoring approaches that indicate the presence, state, or dynamics of latent infection in these hard-to-access compartments.
Ultimately, the scientific payoff the FOA is aiming for is the identification of molecular targets that could be manipulated to address HIV reservoirs more effectively. The announcement frames two broad therapeutic directions: strategies designed to eliminate latent HIV (often associated with approaches that force viral reactivation followed by clearance) and strategies designed to permanently repress HIV (approaches that aim to lock the provirus into a durable silent state). The common thread is that better understanding of host regulatory circuitry, especially under the influence of substance use, could reveal leverage points for interventions that are more precise than current options.
From an administrative standpoint, this is an NIH R01 grant mechanism under the U.S. Department of Health and Human Services, with activity categories listed as education and health and CFDA numbers 93.279 (and an additional listing in the source data). Eligibility is broad and includes many institution types: public and private institutions of higher education, nonprofits with or without 501(c)(3) status, for-profit organizations (including small businesses), and multiple levels of government entities (state, county, city/township, special districts), as well as federally recognized tribal governments and other tribal organizations, and public housing authorities/Indian housing authorities. The funding opportunity was posted and created on December 14, 2015, with an original and current closing date of March 2, 2016. The source data does not specify an award ceiling or the expected number of awards in the provided fields.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-DA-16-012.
Which agency is offering this funding?
This is a National Institutes of Health (NIH) funding opportunity under the U.S. Department of Health and Human Services.
What type of grant mechanism is used?
This opportunity uses the NIH R01 research project grant mechanism and is described as a discretionary research grant.
What is the main purpose of this FOA?
The FOA aims to advance hypothesis-driven research that connects HIV biology, host gene regulation, and substance use or abuse. It encourages mechanistic studies on how epigenomic mechanisms and non-coding RNA pathways influence HIV infection and disease course when drugs of abuse are part of the clinical context.
What scientific areas does the FOA emphasize?
The FOA emphasizes epigenomic regulation (including chromatin organization, DNA methylation, and histone modifications) and non-coding RNA regulation (including regulatory RNAs that do not code for proteins) as they relate to HIV infection, persistence, and progression in the setting of substance use or abuse.
What does the FOA mean by "hypothesis-driven" studies?
Based on the description provided, the FOA is seeking research built around specific testable mechanistic hypotheses that explain how host regulatory mechanisms and non-coding RNA pathways affect HIV outcomes, particularly under the modifying effects of drugs of abuse.
What is the intersection of HIV and substance abuse in this opportunity?
The central theme is understanding how substance use or abuse modifies host molecular regulation (epigenomic and non-coding RNA processes) in ways that shape HIV infection and the course of disease, including persistence and progression.
Does this FOA focus on host-cell mechanisms, viral mechanisms, or both?
The emphasis described is on host regulatory mechanisms (epigenomic states and non-coding RNA pathways) and how they influence HIV integration and the regulation of integrated viral genomes.
Why is HIV integration site selection highlighted?
The FOA highlights integration because HIV integration is not random, and the local chromatin environment can strongly influence whether the virus becomes transcriptionally active or remains silent. Understanding host factors that guide integration site choice and subsequent control of viral expression is a major research priority in this announcement.
How does chromatin environment relate to HIV latency and reservoirs?
According to the FOA description, the epigenetic context around an integrated provirus is closely tied to whether HIV enters or maintains a latent state and becomes part of a long-lived latent reservoir, which is described as a key barrier to curing infection.
What role do non-coding RNAs play in the FOA's research goals?
The FOA is interested in how non-coding RNA pathways (regulatory RNAs that do not code for proteins) shape HIV infection and disease course, including how they may influence HIV integration outcomes and the regulation (activation or silencing) of integrated viral genomes.
What outcomes is the FOA trying to connect molecular regulation to?
The FOA seeks mechanistic work linking host-cell molecular regulation to real outcomes in HIV persistence or progression, specifically considering the modifying effects of drugs of abuse.
Does the FOA address detection or monitoring of latent HIV?
Yes. A stated priority is applying knowledge of epigenomic and non-coding RNA regulation to improve the practical challenge of detecting and tracking latent HIV, especially in cellular reservoirs that are difficult to study and treat.
Which hard-to-study reservoir is specifically called out?
The central nervous system (CNS) is specifically highlighted as an important reservoir of interest.
Why does the FOA emphasize the CNS?
The FOA notes that latency and persistence in brain-associated cells can contribute to long-term complications and may be less responsive to standard treatment strategies, making the CNS a particularly important and challenging compartment for research related to reservoirs and latency.
How might funded studies help with biomarkers or monitoring?
The FOA indicates that clarifying how epigenomic states and non-coding RNAs maintain latency or allow intermittent reactivation could lay groundwork for better biomarkers or monitoring approaches to indicate the presence, state, or dynamics of latent infection in difficult-to-access compartments.
What is the long-term therapeutic goal of the research supported by this FOA?
The FOA aims for identification of molecular targets that could be manipulated to address HIV reservoirs more effectively, informed by host regulatory circuitry and its interaction with substance use.
What broad therapeutic directions are mentioned?
Two broad directions are described: (1) strategies designed to eliminate latent HIV (often involving forcing viral reactivation followed by clearance), and (2) strategies designed to permanently repress HIV (aiming to lock the provirus into a durable silent state).
Is this opportunity focused on basic mechanisms or applied outcomes?
Based on the provided information, it is mechanistic and hypothesis-driven, while also emphasizing practical applications such as detecting/tracking latent HIV and identifying molecular targets relevant to eliminating or durably repressing reservoirs.
What are the activity categories listed for this opportunity?
The activity categories listed are education and health.
What CFDA number is associated with this FOA?
The CFDA number listed is 93.279 (with an additional listing referenced in the source data, but not specified in the provided fields).
Who is eligible to apply?
Eligibility is broad and includes: public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations (including small businesses); state governments; county governments; city or township governments; special district governments; federally recognized tribal governments; other tribal organizations; and public housing authorities/Indian housing authorities.
Are for-profit organizations eligible, including small businesses?
Yes. For-profit organizations are listed as eligible, including small businesses.
Are nonprofits eligible if they do not have 501(c)(3) status?
Yes. The eligibility list explicitly includes nonprofits with or without 501(c)(3) status.
Are tribal entities eligible?
Yes. The eligibility list includes federally recognized tribal governments and other tribal organizations.
Are government entities eligible to apply?
Yes. Multiple levels of government are listed as eligible, including state, county, city/township, and special district governments, as well as public housing authorities/Indian housing authorities.
When was this funding opportunity posted/created?
The opportunity was posted and created on December 14, 2015.
What is the closing date?
The original and current closing date shown is March 2, 2016.
Is the award ceiling provided in the source information?
No. The provided fields do not specify an award ceiling.
Does the source information state the expected number of awards?
No. The provided fields do not list the expected number of awards.
What is a key barrier to curing HIV that this FOA targets indirectly through research?
The FOA describes the long-lived latent reservoir as a key barrier to curing HIV infection and emphasizes research that clarifies how integration site choice and epigenetic context contribute to latency and persistence.
What kinds of epigenomic mechanisms are explicitly mentioned?
The FOA description explicitly mentions chromatin organization, DNA methylation, and histone modifications.
What does the FOA mean by "non-coding RNA pathways" in this context?
In the provided description, non-coding RNA pathways refer to regulatory RNAs that do not code for proteins but can influence gene regulation and, in this FOA's context, potentially influence HIV integration outcomes, transcriptional activity, latency, and disease course in the presence of substance use.
What is the unifying theme across the FOA priorities?
The unifying theme is that host regulatory circuitry (epigenomic and non-coding RNA regulation), especially when altered or modified by drugs of abuse, can shape HIV integration, viral gene expression, latency, reservoir formation/maintenance, and ultimately targets for intervention.
Browse more opportunities from the same agency: HHS-NIH11
Browse more opportunities from the same category: Education, Health
Next opportunity: Maternal, Infant and Early Childhood Home Visiting Program - Formula
Previous opportunity: NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 16 012
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 16 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| Genomic Data Analysis Network: Visualization Genomic Data Center (U24) Apply for RFA CA 15 019 Funding Number: RFA CA 15 019 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) Apply for RFA CA 16 005 Funding Number: RFA CA 16 005 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 16 074 Funding Number: PA 16 074 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $50,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PA 16 075 Funding Number: PA 16 075 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 16 073 Funding Number: PA 16 073 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $225,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PA 16 076 Funding Number: PA 16 076 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Behavioral Science Track Award for Rapid Transition (B/Start)(R03) Apply for PAR 16 071 Funding Number: PAR 16 071 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $75,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 16 072 Funding Number: PA 16 072 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 16 084 Funding Number: PAR 16 084 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $275,000 |
| Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp) Apply for PA 16 086 Funding Number: PA 16 086 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) Apply for PAR 16 105 Funding Number: PAR 16 105 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $400,000 |
| Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03) Apply for RFA DA 16 015 Funding Number: RFA DA 16 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) Apply for PAR 16 111 Funding Number: PAR 16 111 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01) Apply for PAR 16 117 Funding Number: PAR 16 117 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) Apply for PAR 16 123 Funding Number: PAR 16 123 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 17 015 Funding Number: RFA DA 17 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) Apply for PAR 16 122 Funding Number: PAR 16 122 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| The Application of Big Data Analytics to Drug Abuse Research (R01) Apply for PA 16 119 Funding Number: PA 16 119 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 16 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.